Press Releases

and/or
561 News Releases found
Two Promising Memorial Sloan Kettering Studies Featured at American Association for Cancer Research Annual Meeting

Two encouraging Memorial Sloan Kettering Cancer Center (MSK) studies were featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program.
Research Proves Combination Immunotherapy Significantly More Effective than Ipilimumab Alone for Patients with Advanced Melanoma

Positive results from a clinical trial published in <em>The New England Journal of Medicine</em> show that the combination of the immunotherapy drugs ipilimumab (Yervoy<sup>™</sup>) and nivolumab (Opdivo<sup>™</sup>), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.
Memorial Sloan Kettering Opens Pediatric CAR T Cell Clinical Trial

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.
Some Cancer Clinics Spend Thousands More Per Patient in Medicare Dollars

The quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK).
Memorial Sloan Kettering Cancer Center and Weill Cornell to Co-Lead Tuberculosis Research Unit

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health is funding a research collaboration among six institutions in close alliance. The total funding, provided by the National Institute of Allergy and Infectious Diseases, could be up to $45.7 million over seven years.
Pictured: Eytan Stein
Memorial Sloan Kettering Study Shows New Kind of Targeted Drug Has Promise for Leukemia Patients

A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial.
Pictured: Craig Moskowitz
Positive Data from Pivotal Phase III Study Could Improve Standard of Care for Hodgkin Lymphoma Patients

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.
Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients

A number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.
Pictured: Jedd Wolchok, Alexandra Snyder Charen, and Timothy Chan
Memorial Sloan Kettering Team Makes Key Discovery in Understanding Immunotherapy’s Successes—And Its Failures

A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.
MSK West Harrison
Memorial Sloan Kettering Brings Cancer Care Closer to Home for Hudson Valley Residents

Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.